[1] Gong AY, Zhou R, Hu G, et al. MicroRNA513 regulates B7H1 translation and is involved in IFNγinduced B7H1 expression in cholangiocyte[J]. J Immunol, 2009, 182(3):13251333.
[2] Chen J, Feng Y, Lu LB, et al. Interferonγinduced PDL1 surface expression on human oral squamous carcinoma via PKD2 signal pathway[J]. Immunobiology, 2012, 217(4):385393.
[3] Azuma K, Ota K, Kawahara A, et al. Association of PDL1 overexpression with activating EGFR mutations in surgically resected nonsmall cell lung cancer[J]. Ann Oncol, 2014, 25(10):19351940.
[4] Chen L, Gibbons DL, Goswami S, et al. Metastasis is regulated via microRNA200/ZEB1 axis control of tumour cell PDL1 expression andintratumoral immunosuppression[J]. Nat Commun, 2014, 28(5):5241.
[5] Mu CY, Huang JA, Chen Y, et al. High expression of PDL1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation[J]. Med Oncol, 2011, 28(3):682688.
[6] 陈成, 穆传勇, 翟秋霞, 等. PDL1分子在肺癌细胞株上的表达及其生物学意义[J]. 中国肺癌杂志, 2009, 12(8):859863.
[7] Wang L, Ma Q, Chen X, et al. Clinical significance of b7h1 and b71 expression in pancreatic carcinoma[J]. World J Surg, 2010, 34(5):10591065.
[8] Zhang Y, Zhang J, Xu K, et al. PTEN/PI3K/mTOR/B7H1 signaling pathway regulates cell progression and immunoresistance in pancreatic cancer[J]. Hepatogastroenterology, 2013, 60(127):17661772.
[9] Song X, Liu J, Lu Y, et al. Overexpression of B7H1 correlates with malignant cell proliferation in pancreatic cancer[J]. Oncol Rep, 2014, 31(3):11911198.
[10] Okudaira K, Hokari R, Tsuzuki Y, et al. Blockade of B7H1 or B7DC induces an antitumor effect in a mouse pancreatic cancer model[J]. Int J Oncol, 2009, 35(4):741749.
[11] Geng Y, Wang H, Lu C, et al. Expression of costimulatory molecules B7H1, B7H4 and Foxp3+ Tregs in gastric cancer and its clinical significance[J]. Int J Clin Oncol, 2015, 20(2): m273281.
[12] Hua D, Sun J, Mao Y, et al. B7H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma[J]. World J Gastroenterol, 2012, 18(9):971978.
[13] Wang BJ, Bao JJ, Wang JZ, et al. Immunostaining of PD1/PDLs in liver tissues of patients with hepatitis and hepatocellular carcinoma[J]. World J Gastroenterol, 2011, 17(28): 33223329.
[14] Song S, Yuan P, Wu H, et al. Dendritic cells with an increased PDL1 by TGFβ induce T cell anergy for the cytotoxicity of hepatocellular carcinoma cells[J]. Int Immunopharmacol, 2014, 20(1) :117123.
[15] Geng L, Deng J, Jiang G, et al. B7H1 upregulated expression in human hepatocellular carcinoma tissue:correlation with tumor interleukin10 levels[J]. Hepatogastroenterology, 2011, 58(107108): 960964.
[16] Qin X, Liu C, Zhou Y, et al. Cisplatin induces programmed death1ligand 1(PDL1) overexpression in hepatoma H22 cells via Erk /MAPK signaling pathway[J]. Cell Mol Biol (Noisylegrand), 2010, 56 Suppl:OL13661372.
[17] Shi F, Shi M, Zeng Z, et al. PD1 and PDL1 upregulation promotes CD8(+) Tcell apoptosis and postoperative recurrence in hepatocellular carcinoma patients[J]. Int J Cancer, 2011, 128(4): 887896.
[18] Xylinas E, Robinson BD, Kluth LA, et al. Association of Tcell coregulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder[J]. Eur J Surg Oncol, 2014, 40(1):121127.
[19] Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of antiPD1 antibody in cancer[J]. N Engl J Med, 2012, 366(26):24432454.
[20] Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of antiPDL1 antibody in patients with advanced cancer[J]. N Engl J Med, 2012, 366(26):24552465. |